+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 1
Age: 18Years +
FEMALE
ID05942300

Phase I Trial of CPI-0209 with Carboplatin in Patients with Platinum Sensitive Recurrent Ovarian Cancer

Led by Lan Coffman · Updated on 2026-07-08

30

Participants Needed

1

Research Sites

52 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the combination of CPI-0209 and Carboplatin chemotherapy followed by CPI-0209 maintenance in patients with platinum-sensitive recurrent ovarian cancer. This Phase 1 trial focuses on improving treatment options after previous therapies like PARP inhibitors or bevacizumab, which have modest benefits and may reduce platinum response. The study aims to assess whether CPI-0209 can enhance sensitivity to platinum-based chemotherapy and extend the disease-free period by targeting mechanisms that promote chemotherapy resistance and cancer growth. Participants receive oral CPI-0209 at doses of 100 mg or 150 mg along with intravenous Carboplatin administered according to institutional standards. The treatment is given sequentially, starting with the combination therapy followed by CPI-0209 maintenance. This approach is designed to block stromal-mediated resistance and metastasis, potentially improving chemotherapy effectiveness in this patient group. During the study, participants undergo assessments including safety monitoring for adverse events, evaluation of overall response rate, and progression-free survival for up to 5.5 years. Researchers determine the maximum tolerated dose of CPI-0209 over up to 24 months. Participants must comply with study protocols, provide informed consent, and attend scheduled visits for laboratory tests and imaging to monitor disease progression and treatment effects throughout the trial duration, which lasts until July 2029.

CONDITIONS

Brief Title

CPI-0209 Plus Carboplatin in Patients With Platinum Sensitive Recurrent Ovarian Cancer

Research Team

K

Kelsey Mitch, RN

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here